BioPharm America

Sep. 16, 2009-Sep. 18, 2009
Marriott San Francisco
San Francisco, CA
www.ebdgroup.com/bpa

Description:

The Benefits of Focus: Has the Industry’s Focus on Specialty Products Helped to Drive Valuations Higher?

Michael Fleming an executive in the Business Development Practice at Campbell Alliance will moderate a panel discussion at this event titled "The Benefits of Focus: Has the Industry’s Focus on Specialty Products Helped to Drive Valuations Higher?" Panelists will include executives from UCB, Onyx, Bayer, and Millennium.

Abstract:

The Benefits of Focus: Has the Industry’s Focus on Specialty Products Helped to Drive Valuations Higher?

Moderator:
Michael Flemming, Executive Advisory Group Member, Business Development Practice, Campbell Alliance

Panelists:
Fabrice Egros, Senior VP, Global Business Development, UCB
Juergen Lasowski, Senior VP, Corporate Development, Onyx Pharmaceuticals
Anna Protopapas, Senior VP, Corporate Development and Strategy, Millennium: The Takeda Oncology Company
Christopher Seaton, Senior VP, Global Transactions, Bayer HealthCare

There used to be a relatively strong distinction between the specialty companies that had a strong therapeutic area focus and the “big pharma” companies with a primary care focus and product development efforts in a number of different disease areas. For many years the specialty companies have enjoyed higher multiples than those for big pharma.
Recently, however, big pharma has been moving away from the primary care focus that has defined them. This has mixed implications for the specialty companies. On the one hand, many specialty companies have been acquired over the last few years at truly eye-catching multiples to revenue. On the other, big pharma may be crowding out the specialty companies as they acquire more and more specialty programs and embrace narrower market opportunities.

This panel of experts will provide a review of licensing trends in specialty therapeutic categories and consider the implications for these markets over the next 5-10 years.

View Entire Event Calendar

Don't Miss